Genestack provides missing link between data and analysis for drug discovery
Imad I. Yassin appointed Vice President of Sales and Marketing for Genestack
“Genestack is providing an essential missing link between data and its analysis,” says Imad I. Yassin, recently appointed Vice President of Sales and Marketing for Genestack, the Cambridge-based biodata management company.
Imad I. Yassin (credit Genestack)
Yassin says:
Yassin brings experience of fast-tracking early stage companies in the genomics space. The most recent, Integromics, was acquired by PerkinElmer to become part of its global informatics solution.
Genestack CEO Dr Misha Kapushesky says:
Genestack has developed a set of easy-to-use tools that allow scientists involved in drug discovery to gain insights from the data without the need for sophisticated programming knowledge. The platform enables the collection, federation, and tracking of data and its provenance across different sources – public and internal – for analysis and visualization.
Yassin continues:
It is not just access to public data. Most pharmas have generated their own data over the years and this is locked in silos, held in different formats and created for different uses. Genestack can be used alongside existing legacy systems to help biologists gain access to all of this data. It has a powerful metadata system that describes the data and makes it indexed and searchable. This is critical, e.g., for rapid, interactive cohort selection and population level genotype association analysis.
“Genestack is solving some of the biggest pain points experienced by large pharma,” Yassin concludes.
Outside of Genestack, Yassin sits on the Advisory Board of the World Leaders Forum and of the Singularity University, which has evolved from a Silicon Valley think tank. He is also the chair of the Idris Foundation, which aims to improve the lives of refugees through technology.
Source:
No hay comentarios:
Publicar un comentario